Novo NordiskNovo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
Tag Archive for: Novo Nordisk
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.
Novo Nordisk realises a major expansion in Clayton, NC (USA). The project will enhance Novo Nordisk’s manufacturing capabilities with more than 1.4 million square feet of new space.
A German-Danish team has discovered that a truncated version of the enzyme adenlyate cyclase 3 can be targeted to transform fat-storing white adipocytes into fat-burning brown adipocytes.
Novo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.
In the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.
With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.
Novo Nordisk A/S invests €726m to expand facilities and to produce APIs to supply the company’s global clinical trials.